Home » Stocks » GNCA

Genocea Biosciences, Inc. (GNCA)

Stock Price: $2.25 USD -0.07 (-3.02%)
Updated May 12, 2021 3:59 PM EDT - Market closed
Market Cap 126.29M
Revenue (ttm) 1.36M
Net Income (ttm) -42.84M
Shares Out 66.16M
EPS (ttm) -0.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $2.25
Previous Close $2.32
Change ($) -0.07
Change (%) -3.02%
Day's Open 2.31
Day's Range 2.22 - 2.37
Day's Volume 300,868
52-Week Range 1.74 - 5.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Genocea Biosciences (GNCA) delivered earnings and revenue surprises of 15.00% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

GEN-011 and GEN-009 immuno-oncology programs continue to advance

1 week ago - GlobeNewsWire

CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first quar...

2 weeks ago - GlobeNewsWire

ASC, BCEI, XOG, GNCA, and GNLN have been added to the Zacks Rank #5 (Strong Sell) List on April 13, 2021

Other stocks mentioned: ASC, BCEI, GNLN, XOG
4 weeks ago - Zacks Investment Research

Pro-tumor effects detected as early as four days after Inhibigen administration

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chi...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chi...

2 months ago - GlobeNewsWire

GEN-011 and GEN-009 clinical trials continue to advance

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quar...

3 months ago - GlobeNewsWire

Study validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigensof anti-tumor T cell responses and excluding Inhibigens™, or neoantigens of pro-tumor T cell...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chi...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chi...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies

6 months ago - GlobeNewsWire

Call scheduled for November 9th at 8:30 a.m. EST Call scheduled for November 9th at 8:30 a.m. EST

6 months ago - GlobeNewsWire

Genocea Biosciences, Inc's (GNCA) CEO Chip Clark on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quart...

6 months ago - GlobeNewsWire

Is (GNCA) Outperforming Other Medical Stocks This Year?

6 months ago - Zacks Investment Research

Will showcase clinical and immune response s from the ongoing GEN-009 Phase 1/2a trial

6 months ago - GlobeNewsWire

Genocea's (GNCA) investigational new drug application to initiate a clinical study to evaluate its neoantigen-specific cell therapy candidate, GEN-011 in cancer patients gets FDA clearance.

7 months ago - Zacks Investment Research

Novel adoptive T cell therapy targets checkpoint-refractory solid tumors with neoantigen-specific T cells from peripheral blood Novel adoptive T cell therapy targets checkpoint-refractory solid tumors w...

7 months ago - GlobeNewsWire

Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit to PD-1 inhibitor therapy

7 months ago - GlobeNewsWire

Investors need to pay close attention to Genocea Biosciences (GNCA) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that ...

8 months ago - GlobeNewsWire

Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Upcoming GEN-009 data update planned for July 30th at 8 a.m. EDT Filed IND application for GEN-011 and is working with the FDA to provide additional information Private Placement with Leading Life...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has e...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced updates...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its second q...

9 months ago - GlobeNewsWire

Inhibigens (inhibitory antigens) are detrimental an otherwise protective immunotherapy

10 months ago - GlobeNewsWire

Preliminary clinical data expected mid-2021 Preliminary clinical data expected mid-2021

10 months ago - GlobeNewsWire

Data show immune responses occur rapidly after only two vaccinations and  can be sustained for more than one year

11 months ago - GlobeNewsWire

CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has ...

11 months ago - GlobeNewsWire

GEN-011 IND filing by end of Q2 with preliminary clinical data expected in 1H 2021 GEN-011 IND filing by end of Q2 with preliminary clinical data expected in 1H 2021

1 year ago - GlobeNewsWire

Call scheduled for May 12th from 12:00 – 1:30 p.m. EDT Call scheduled for May 12th from 12:00 – 1:30 p.m. EDT

1 year ago - GlobeNewsWire

Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: ACRX, AVGR, GOSS, VFF
1 year ago - Zacks Investment Research

Genocea Biosciences: Don't Sleep On This Small Biotech

1 year ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor in Genocea Biosciences, Inc. (GNCA).

1 year ago - Zacks Investment Research

Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Genocea Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

ATLAS™ identifies naturally occurring neoantigen-specific inhibitory T cell responses that are augmented after vaccination

1 year ago - GlobeNewsWire

Genocea Biosciences Inc (GNCA) CEO Chip Clark on Q3 2019 Results Earnings Call - Transcript

1 year ago - Seeking Alpha

Generated unprecedented 98% GEN-009 immune response frequency with ATLAS™ Continued advancement of GEN-011, expect to file an IND in first half of 2020 Entered into a common stock purchase agreeme...

1 year ago - GlobeNewsWire

Additional p ositive GEN-009 c linical i mmunogenicity d ata d riven by ATLAS™ to be p resented at ESMO

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Cl...

1 year ago - GlobeNewsWire

Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Genocea recently reported strong immunogenicity data from its phase 1/2a study using its neoantigen vaccine GEN-009 to treat patients with multiple types of cancer.

1 year ago - Seeking Alpha

Genocea Biosciences recently delivered robust data for the Phase 1/2 trial studying GEN-009 at the 2019 Annual Meeting of the American Society of Clinical Oncology.

1 year ago - Seeking Alpha

ATLAS was used to select HSV2 antigens incorporated into a therapeutic vaccine that reduced symptoms but not enough to advance into phase 3 studies.

1 year ago - Seeking Alpha

About GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell the... [Read more...]

Industry
Biotechnology
IPO Date
Feb 5, 2014
CEO
William Clark
Employees
72
Stock Exchange
NASDAQ
Ticker Symbol
GNCA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for GNCA stock is "Strong Buy." The 12-month stock price forecast is 6.68, which is an increase of 196.89% from the latest price.

Price Target
$6.68
(196.89% upside)
Analyst Consensus: Strong Buy